β-Адреноблокаторы и комбинированные низкодозовыепрепараты при лечении артериальной гипертонии
β-Адреноблокаторы и комбинированные низкодозовыепрепараты при лечении артериальной гипертонии
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Список литературы
1. Ивлева А.Я., Сивкова Е.Б. Современные представления о клинической ценности β-адреноблокаторов. М., 2004.
2. Elliott W, Meyer P. Incident diabetes in clinical trial of antihypertensive drugs:a network meta-analysis. Lancet 2007; 369: 201–7.
3. Benetos A, Consoli S, Safavian A et al. Efficacy,safety and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension. Am Heart J 2000; 140 (4): E11.
4. Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987; 8: 103–13.
5. Buhtel FR, Berglund G, Anderson OK et al. Smoking status and cardioselective beta-blocade antihypertensive therapy: the Bisoprolol International Multicentre Study (BIMS). J Hypertens 1986; 4: 144–6.
6. Van der Ven LM. Age-dependent differences in the efficacy and tolerability of different classes of antihypertensive drugs. Clin Drug Invest 1997; 1: 16–22.
7. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121–3.
8. Ситникова М.Ю., Иванов С.Г., Хмельницкая К.А. Плейотропные эффекты β-адреноблокаторов в терапии сердечно-сосудистых заболеваний: влияние на перекисное окисление липидов, свойства эндотелия и эволюцию атеросклероза. Кардиология. 2009; 6: 61–6.
9. SHEP Cooperative Reseach Group. Prevention of stroke by antihypertensive drug treatment in older person withisolated systolis hypertension. Final results of the Systolic Hypertension in Elderly Program (SHEP). JAMA 1991; 265: 3255–64.
10. Bakris G, Molitch M, Hewkin A et al. Sowers. STAR investigators. Differences in glucose tolerance between fixed (dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592–7.
11. Fernandez R, Puig JG, Rodriguez-Perez JC et al., on behalf of the TRAVEND Study Group. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Human Hypertens 2001; 15: 849–56.
12. Диагностика и лечение артериальной гипертензии. Российские рекомендации. Кардиоваск. тер. и проф. 2008; Прил. 2.
13. Frishman WH, Burris JF, Mroczek WJ et al. First-line therapy jhtion with lowedose Bisoprolol fumarate and lowe-dose Hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995; 35: 182–8.
2. Elliott W, Meyer P. Incident diabetes in clinical trial of antihypertensive drugs:a network meta-analysis. Lancet 2007; 369: 201–7.
3. Benetos A, Consoli S, Safavian A et al. Efficacy,safety and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension. Am Heart J 2000; 140 (4): E11.
4. Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987; 8: 103–13.
5. Buhtel FR, Berglund G, Anderson OK et al. Smoking status and cardioselective beta-blocade antihypertensive therapy: the Bisoprolol International Multicentre Study (BIMS). J Hypertens 1986; 4: 144–6.
6. Van der Ven LM. Age-dependent differences in the efficacy and tolerability of different classes of antihypertensive drugs. Clin Drug Invest 1997; 1: 16–22.
7. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121–3.
8. Ситникова М.Ю., Иванов С.Г., Хмельницкая К.А. Плейотропные эффекты β-адреноблокаторов в терапии сердечно-сосудистых заболеваний: влияние на перекисное окисление липидов, свойства эндотелия и эволюцию атеросклероза. Кардиология. 2009; 6: 61–6.
9. SHEP Cooperative Reseach Group. Prevention of stroke by antihypertensive drug treatment in older person withisolated systolis hypertension. Final results of the Systolic Hypertension in Elderly Program (SHEP). JAMA 1991; 265: 3255–64.
10. Bakris G, Molitch M, Hewkin A et al. Sowers. STAR investigators. Differences in glucose tolerance between fixed (dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592–7.
11. Fernandez R, Puig JG, Rodriguez-Perez JC et al., on behalf of the TRAVEND Study Group. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Human Hypertens 2001; 15: 849–56.
12. Диагностика и лечение артериальной гипертензии. Российские рекомендации. Кардиоваск. тер. и проф. 2008; Прил. 2.
13. Frishman WH, Burris JF, Mroczek WJ et al. First-line therapy jhtion with lowedose Bisoprolol fumarate and lowe-dose Hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995; 35: 182–8.
Авторы
Р.И.Стрюк
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.